Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II outpatient risk-adjusted rituximab-based salvage chemotherapy for relapsed or refractory CD20-positive non-Hodgkin lymphoma
ACTRN12606000386538Phase 2Completed
- Sponsor
- Associate Professor Andrew Spencer
- Start
- Mar 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab, vinorelbine, gemcitabine, pegfilgrastim, ifosfamide and 2 more in non-Hodgkin lymphoma (NHL) and CD20-positive B-cell lymphoma (3 arms), sponsored by Associate Professor Andrew Spencer. Primary endpoint: Safety. Started Mar 2006; status: completed.
02
Drugs
rituximabvinorelbinegemcitabinepegfilgrastimifosfamide
03
Conditions
non-Hodgkin lymphoma (NHL)CD20-positive B-cell lymphoma
Beyond the preview
Go deeper on ACTRN12606000386538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000386538.